Skip to main content
Premium Trial:

Request an Annual Quote

Health Discovery, NeoGenomics Sign Cancer Testing License Pact

NEW YORK (GenomeWeb News) – Molecular diagnostic technologies developer Health Discovery said today that it has licensed some of its biomarker-based testing tools for hematopoietic and solid tumor cancers to NeoGenomics for $1 million in cash, 1.4 million shares in NeoGenomics stock, milestone payments of up to $5 million, and ensuing royalties.

Under the agreement, NeoGenomics will commercialize laboratory-developed tests based on HDC technologies for a range of cancer types, but HDC retains the rights to in vitro diagnostic test development and its pre-existing licenses remain in effect.

The license does not cover use of HDC's testing tools for breast cancer, which it previously licensed to Quest Diagnostics and Smart Personalized Medicine, or its test for retina cancer, which it has licensed to Retinalyze.

HDC Chairman and CEO Stephen Barnhill said in a statement that the agreement covers tests for prostate cancer, pancreatic cancer, colon cancer, and cytogenenetics and flow cytometry software systems.

On top of the cash and common stock at the front of the deal, NeoGenomics will make milestone payments in cash or stock based on sublicensing and other revenues generated from products and services.

NeoGenomics will pay HDC milestone payments in increments of $500,000 for every $2 million in revenue up to a total of $5 million. After a total of $20 million in cumulative revenue has been recognized, NeoGenomics will pay a royalty of 6.5 percent on product sales and it will share profits from sub-licensing agreements. NeoGenomics also will pay a royalty of 50 percent of the revenue coming from any sub-licensing arrangements for the Cytogenetics Interpretation System and the Flow Cytometry System.

Headquartered in Fort Myers, Fla., CLIA-certified NeoGenomics also has labs in Nashville, Tenn.; Irvine, Calif.; and Tampa, Fla.

Barnhill said that NeoGenomics "has agreed to use its best efforts to complete the development of these tests and have a first commercial use of products in the next 12 months, subject to extensions if required."

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.